JP2019516785A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516785A5
JP2019516785A5 JP2019508294A JP2019508294A JP2019516785A5 JP 2019516785 A5 JP2019516785 A5 JP 2019516785A5 JP 2019508294 A JP2019508294 A JP 2019508294A JP 2019508294 A JP2019508294 A JP 2019508294A JP 2019516785 A5 JP2019516785 A5 JP 2019516785A5
Authority
JP
Japan
Prior art keywords
disease
cancer
binding domain
seq
domain according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019508294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516785A (ja
JP7133544B2 (ja
Filing date
Publication date
Priority claimed from GBGB1607636.6A external-priority patent/GB201607636D0/en
Priority claimed from GBGB1607828.9A external-priority patent/GB201607828D0/en
Application filed filed Critical
Priority claimed from PCT/EP2017/060266 external-priority patent/WO2017191062A1/en
Publication of JP2019516785A publication Critical patent/JP2019516785A/ja
Publication of JP2019516785A5 publication Critical patent/JP2019516785A5/ja
Priority to JP2022075986A priority Critical patent/JP2022115961A/ja
Application granted granted Critical
Publication of JP7133544B2 publication Critical patent/JP7133544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019508294A 2016-05-01 2017-04-28 親和性を操作した血清タンパク質担体結合ドメイン Active JP7133544B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022075986A JP2022115961A (ja) 2016-05-01 2022-05-02 親和性を操作した血清タンパク質担体結合ドメイン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1607636.6 2016-05-01
GBGB1607636.6A GB201607636D0 (en) 2016-05-01 2016-05-01 Molecules & method
GBGB1607828.9A GB201607828D0 (en) 2016-05-04 2016-05-04 Method
GB1607828.9 2016-05-04
PCT/EP2017/060266 WO2017191062A1 (en) 2016-05-01 2017-04-28 Affinity engineered serum protein carrier binding domain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022075986A Division JP2022115961A (ja) 2016-05-01 2022-05-02 親和性を操作した血清タンパク質担体結合ドメイン

Publications (3)

Publication Number Publication Date
JP2019516785A JP2019516785A (ja) 2019-06-20
JP2019516785A5 true JP2019516785A5 (enExample) 2020-05-28
JP7133544B2 JP7133544B2 (ja) 2022-09-08

Family

ID=58707502

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508294A Active JP7133544B2 (ja) 2016-05-01 2017-04-28 親和性を操作した血清タンパク質担体結合ドメイン
JP2022075986A Abandoned JP2022115961A (ja) 2016-05-01 2022-05-02 親和性を操作した血清タンパク質担体結合ドメイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022075986A Abandoned JP2022115961A (ja) 2016-05-01 2022-05-02 親和性を操作した血清タンパク質担体結合ドメイン

Country Status (8)

Country Link
US (1) US11466076B2 (enExample)
EP (1) EP3452506B1 (enExample)
JP (2) JP7133544B2 (enExample)
CN (1) CN109071643B (enExample)
BR (1) BR112018071288A2 (enExample)
CA (1) CA3022494A1 (enExample)
ES (1) ES3035839T3 (enExample)
WO (1) WO2017191062A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201811368D0 (en) * 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
EP3904378A1 (en) * 2020-04-29 2021-11-03 Hober Biotech AB Bispecific protein
JP2023547795A (ja) 2020-10-15 2023-11-14 ユーシービー バイオファルマ エスアールエル Ｃｄ４５を多量体化する結合分子
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004253738A1 (en) 2003-07-01 2005-01-13 Ucb Pharma S.A. Modified antibody Fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
JP5592792B2 (ja) * 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
LT2334705T (lt) 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
SI2776466T1 (sl) * 2011-11-11 2017-12-29 Ucb Biopharma Sprl Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
WO2015006337A2 (en) * 2013-07-08 2015-01-15 Nanjingjinsirui Science & Technology Biology Corporation Compositions and methods for increasing protein half-life in a serum
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct

Similar Documents

Publication Publication Date Title
JP2019516785A5 (enExample)
JP2020513804A5 (enExample)
JP2019519216A5 (enExample)
HRP20141214T1 (hr) Molekule antitijela sa specifiäśnosti za humani 6-il
JP2015525768A5 (enExample)
JP2019503167A5 (enExample)
JP2019514876A5 (enExample)
JP2011083291A5 (enExample)
JP2019506841A5 (enExample)
JP2016515524A5 (enExample)
JP2018198596A5 (enExample)
JP2016517273A5 (enExample)
JP2018538281A5 (enExample)
JP2014515602A5 (enExample)
JP2010273685A5 (enExample)
JP2017536412A5 (enExample)
JP2008525033A5 (enExample)
JP2017500035A5 (enExample)
JP2015523323A5 (enExample)
HRP20231264T1 (hr) Protutijela protiv csf-1r
JP2015096070A5 (enExample)
JP2018524001A5 (enExample)
WO2017009308A3 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP2015521039A5 (enExample)
JP2012505657A5 (enExample)